CN110483642B - Monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof - Google Patents
Monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof Download PDFInfo
- Publication number
- CN110483642B CN110483642B CN201810464311.1A CN201810464311A CN110483642B CN 110483642 B CN110483642 B CN 110483642B CN 201810464311 A CN201810464311 A CN 201810464311A CN 110483642 B CN110483642 B CN 110483642B
- Authority
- CN
- China
- Prior art keywords
- antibody
- application
- enoyl
- acyl carrier
- carrier protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The application provides a monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof. Experimental results show that the antibody can be applied to antibody chip reactions, immunoprecipitation, western Blotting and detection of the content of enoyl-acyl carrier protein reductase in bacteria, plants, protozoa and mitochondria, which are researched by aiming at the protein.
Description
Technical Field
The application belongs to the field of biological medicine, and in particular relates to a monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof.
Background
Enoyl-acyl carrier protein reductase (ENR) (EC 1.3.1.9) is a key enzyme involved in the type II Fatty Acid Synthesis (FAS) pathway of bacteria, plants, protozoa and mitochondria. ENR is an attractive target for the discovery of a narrow spectrum antibacterial drug because of its important role in the metabolism of many bacterial species and its sequence conservation.
Bacterial ENR sequences and structural organization are significantly different from mammalian fatty acid biosynthetic enzymes. Harmful pathogens such as mycobacterium tuberculosis and plasmodium falciparum use the type II fatty acid synthesis system, rather than mammals or fungi containing a type I fatty acid synthesis pathway consisting of one or two multifunctional enzymes. Thus, specific inhibitors of ENR are attractive antibiotic candidates. For example, at lower concentrations triclosan and triclocarban provide bacteriostatic effects by binding to ENR.
Antibodies targeting RNR may aid in antibiotic screening. There are no antibodies specifically targeted to enoyl-acyl carrier protein reductases on the market today and there is a lack of effective antibody tools at the proteomics level for this field of research.
Disclosure of Invention
The application aims to provide a monoclonal antibody of ENR, which can be used as a tool for researching targeted proteins so as to realize deeper research on protein expression changes and protein network patterns in different bacteria, plants, protozoa and mitochondria.
In a first aspect of the application there is provided a heavy chain variable region of an antibody, said heavy chain variable region having one or more complementarity determining region CDRs:
VH CDR1 shown in SEQ ID NO. 1,
VH CDR2 shown in SEQ ID NO. 2, and
VH CDR3 shown in SEQ ID No. 3;
preferably, the heavy chain variable region has the amino acid sequence shown in SEQ ID NO. 4.
In a second aspect of the application there is provided an antibody heavy chain having a heavy chain variable region and a heavy chain constant region according to the first aspect of the application.
In another preferred embodiment, the heavy chain constant region is murine.
In a third aspect of the application, there is provided a light chain variable region of an antibody, said light chain variable region having one or more complementarity determining region CDRs:
VL CDR1 shown in SEQ ID No. 5,
VL CDR2 shown in SEQ ID NO. 6, and
VL CDR3 shown in SEQ ID NO. 7;
preferably, the light chain variable region has the amino acid sequence shown in SEQ ID NO. 8.
In a fourth aspect of the application there is provided an antibody light chain having a light chain variable region and a light chain constant region according to the third aspect of the application.
In another preferred embodiment, the constant region of the light chain is murine.
In a fifth aspect of the application, there is provided an antibody having:
(1) A heavy chain variable region according to the first aspect of the application; and/or
(2) A light chain variable region according to the third aspect of the application;
preferably, the antibody has: a heavy chain according to the second aspect of the application; and/or a light chain according to the fourth aspect of the application.
In another preferred embodiment, the antibody is an antibody specific for an enoyl-acyl carrier protein reductase polypeptide.
In another preferred embodiment, the enoyl-acyl carrier protein reductase polypeptide is selected from the group consisting of: 'MLRRGFLSRI', 'PINPADINTI', 'GANSAVGQAV', 'AKFKDAAAAA', or a combination thereof.
In another preferred embodiment, the antibody comprises: single chain antibodies (scFv), diabodies, monoclonal antibodies, chimeric antibodies, murine antibodies.
In a sixth aspect of the present application, there is provided a recombinant protein having:
(i) The sequence of the heavy chain variable region of the first aspect of the application, the sequence of the heavy chain of the second aspect of the application, the sequence of the light chain variable region of the third aspect of the application, the sequence of the light chain of the fourth aspect of the application, or the sequence of the antibody of the fifth aspect of the application; and
(ii) Optionally a tag sequence to assist expression and/or purification.
In another preferred embodiment, the tag sequence is selected from the group consisting of: 6 XHis tag, GGGS sequence, FLAG tag.
In another preferred embodiment, the recombinant protein comprises a bispecific antibody, a chimeric antibody.
In a seventh aspect of the application, there is provided a polynucleotide encoding a polypeptide selected from the group consisting of:
(1) The heavy chain variable region of the first aspect of the application, the heavy chain of the second aspect of the application, the light chain variable region of the third aspect of the application, the light chain of the fourth aspect of the application, or the antibody of the fifth aspect of the application; or (b)
(2) The recombinant protein according to the sixth aspect of the present application.
In an eighth aspect of the application there is provided a vector comprising a polynucleotide according to the seventh aspect of the application.
In another preferred embodiment, the carrier comprises: bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses and retroviruses.
In a ninth aspect of the application there is provided a genetically engineered host cell comprising a vector or genome according to the eighth aspect of the application incorporating a polynucleotide according to the seventh aspect of the application.
In a tenth aspect of the present application there is provided a conjugate comprising:
(a) An antibody according to the fifth aspect of the application or a recombinant protein according to the sixth aspect of the application; and
(b) A detectable label attached to the antibody or recombinant protein of (a).
In another preferred embodiment, the detectable label is selected from the group consisting of: biotin, fluorescein, chemiluminescent groups, fluorescent proteins, enzymes, colloidal gold, colored magnetic beads, latex particles, biotin labels, radionuclides, antibodies, ligands, antigens, receptors, nanoparticles, or combinations thereof.
In another preferred embodiment, the nanoparticle is selected from the group consisting of: gold nanoparticles, silver nanoparticles, quantum dots, or combinations thereof.
In another preferred embodiment, the enzyme is selected from the group consisting of: horseradish peroxidase, acid phosphatase, or a combination thereof.
In an eleventh aspect of the present application, there is provided an inspection article comprising:
(1) An antibody according to the fifth aspect of the application, a recombinant protein according to the sixth aspect of the application, or a conjugate according to the tenth aspect of the application; and
(2) Optionally a buffer solution or buffer.
In another preferred embodiment, the detection preparation is used for detecting enoyl-acyl carrier protein reductase.
In another preferred embodiment, the detection article comprises: test reagents, lateral flow sheets, chips, test strips, test plates, test strips.
In another preferred embodiment, the test strip includes: a detection zone to which another antibody (antibody two) against the enoyl-acyl carrier protein reductase is immobilized, the antibody two being for capturing the enoyl-acyl carrier protein reductase.
In another preferred embodiment, the test strip includes: a quality control region to which an antibody (secondary antibody) that binds to an antibody (primary antibody) against an enoyl-acyl carrier protein reductase is immobilized, the secondary antibody being used to capture the antibody (primary antibody) against an enoyl-acyl carrier protein reductase.
In another preferred embodiment, the test strip is selected from the group consisting of: porous plates, preferably 96-well plates, PVDF membranes.
In another preferred embodiment, the antibody (secondary antibody) that binds to an antibody (primary antibody) directed against an enoyl-acyl carrier protein reductase is selected from the group consisting of: HRP-labeled goat anti-mouse IgG secondary antibody.
In a twelfth aspect of the application there is provided the use of a heavy chain variable region according to the first aspect of the application, a heavy chain according to the second aspect of the application, a light chain variable region according to the third aspect of the application, a light chain according to the fourth aspect of the application, an antibody according to the fifth aspect of the application, a recombinant protein according to the sixth aspect of the application, or a conjugate according to the tenth aspect of the application, or a detection article according to the eleventh aspect of the application, for the preparation of a detection article or kit for detecting an enoyl-acyl carrier protein reductase in a microorganism.
In another preferred embodiment, the detection article comprises a chip, an immune microparticle coated with an antibody.
In a thirteenth aspect of the application, there is provided a detection kit comprising an antibody according to the fifth aspect of the application, a recombinant protein according to the sixth aspect of the application, or a conjugate according to the tenth aspect of the application or a detection article according to the eleventh aspect of the application.
In a fourteenth aspect of the present application, there is provided a method for detecting an enoyl-acyl carrier protein reductase in a microorganism, the method comprising the steps of:
(a) Providing a sample to be detected;
(b) Mixing the sample with an antibody according to the fifth aspect of the application, a recombinant protein according to the sixth aspect of the application, a conjugate according to the tenth aspect of the application, or a detection article according to the eleventh aspect of the application to form a mixture;
(c) Detecting the presence or absence of an "antibody-enoyl-acyl carrier protein reductase complex" in the mixture, wherein the presence of the complex, if any, indicates the presence of enoyl-acyl carrier protein reductase in the sample; if the complex is not present, it indicates that no enoyl-acyl carrier protein reductase is present in the sample.
It is understood that within the scope of the present application, the above-described technical features of the present application and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
Drawings
FIG. 1 shows a specific process route for antibody production.
FIG. 2 is a graph of the results of an antibody endogenous protein immunoblot.
FIG. 3 is a graph showing the results of the fluorescence reaction of the antibody chip.
FIG. 4 shows a standard graph of the detection of the content of enoyl-acyl carrier protein reductase.
Detailed Description
The present inventors have unexpectedly obtained a high affinity mab (murine mab) that recognizes and binds to enoyl-acyl carrier protein reductase (ENR) by extensive and intensive studies, which can be applied to antibody chip reactions, immunoprecipitation, western Blotting, and detection of the content of enoyl-acyl carrier protein reductase in bacteria, plants, protozoa, and mitochondria for the protein studies. On this basis, the present application has been completed.
Before describing the present application, it is to be understood that this application is not limited to the particular methodology and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, as the scope of the present application will be limited only by the appended claims.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. As used herein, when used in reference to a specifically recited value, the term "about" means that the value can vary no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, the preferred methods and materials are described herein.
Antibodies to
As used herein, the term "antibody" consists of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to the heavy chain by a covalent disulfide bond. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end followed by a plurality of constant regions. One end of each light chain is provided with a variable region (VL) and the other end is provided with a constant region; the constant region of the light chain is opposite the first constant region of the heavy chain and the variable region of the light chain is opposite the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.
As used herein, the term "variable" means that certain portions of the variable regions in an antibody differ in sequence, which results in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the antibody variable region. It is concentrated in three fragments in the light and heavy chain variable regions called Complementarity Determining Regions (CDRs) or hypervariable regions. The more conserved parts of the variable region are called Framework Regions (FR). The variable regions of the natural heavy and light chains each comprise four FR regions, which are generally in a β -sheet configuration, connected by three CDRs forming the connecting loops, which in some cases may form part of the β -sheet structure. The CDRs in each chain are held closely together by the FR regions and together with the CDRs of the other chain form the antigen binding site of the antibody (see Kabat et al, NIH publication No.91-3242, vol. I, pp. 647-669 (1991)). The constant regions are not directly involved in binding of the antibody to the antigen, but they exhibit different effector functions, such as participation in antibody-dependent cytotoxicity of the antibody.
As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population, i.e., the individual antibodies contained in the population are identical, except for a few naturally occurring mutations that may be present. Monoclonal antibodies are highly specific for a single antigenic site. Moreover, unlike conventional polyclonal antibody preparations (typically having different antibodies directed against different determinants), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture and are not contaminated with other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring any particular method for producing the antibody.
The application also includes monoclonal antibodies having the corresponding amino acid sequences of the anti-enoyl-acyl carrier protein reductase (ENR) monoclonal antibodies, monoclonal antibodies having the variable region chains of the anti-enoyl-acyl carrier protein reductase (ENR) monoclonal antibodies, and other proteins or protein conjugates and fusion expression products having these chains. In particular, the application includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) having a light chain and a heavy chain comprising a hypervariable region (complementarity determining region, CDR), provided that the hypervariable region is identical or at least 90% homologous, preferably at least 95% homologous, to the hypervariable regions of the light chain and heavy chain of the application.
As known to those skilled in the art, conjugates include: detectable labels such as colloidal gold labels, colored magnetic beads or latex particles, biotin labels, horseradish peroxidase labels, radionuclide labels, fluorescein labels, nanoparticle labels, conjugates formed by binding the anti-enoyl-acyl carrier protein reductase (ENR) monoclonal antibodies or fragments thereof. The application also includes a cell surface marker or antigen that binds to the anti-enoyl-acyl carrier protein reductase (ENR) monoclonal antibody or fragment thereof.
The application includes not only intact monoclonal antibodies but also immunologically active antibody fragments such as Fab or (Fab') 2 Fragments; antibody heavy chain; an antibody light chain.
As used herein, the terms "heavy chain variable region" and "V H "interchangeably used.
As used herein, the term "variable region" is used interchangeably with "complementarity determining region (complementarity determining region, CDR)".
In a preferred embodiment of the application, the heavy chain variable region (VH) of the antibody has complementarity determining region CDRs selected from the group consisting of:
VH CDR1 with amino acid sequence LEGANNIRRQT (SEQ ID No.: 1);
VH CDR2 with amino acid sequence IRRMYFGGP (SEQ ID No.: 2);
VH CDR3 with amino acid sequence gifval (SEQ ID No.: 3);
in another preferred embodiment, the amino acid sequence of the heavy chain variable region (82 aa) is:
SVPRMYLQTAANLEGANNIRRQTPAAPLLQTSVIRQTIRRMYFGGPTTLQEEGGPAVANFFTLGIFVA TNAVSPPQQLTEGR(SEQ ID NO.:4);
in a preferred embodiment of the present application, the heavy chain of the antibody comprises the heavy chain variable region described above and a heavy chain constant region, which may be murine.
As used herein, the terms "light chain variable region" and "V L "interchangeably used.
In a preferred embodiment of the application, the light chain variable region (VL) of the antibody according to the application has complementarity determining regions CDRs selected from the group consisting of:
VL CDR1 having the amino acid sequence IRVATT (SEQ ID NO: 5);
VL CDR2, having the amino acid sequence PSSRRQT (SEQ ID NO.: 6);
VL CDR3 having the amino acid sequence YFMMRIT (SEQ ID NO: 7);
in another preferred embodiment, the amino acid sequence of the light chain variable region (81 aa) is:
VARTNIMMFSPAVATIRVATTPPGVAQQLEPSSVPQTTEPSSRRQTMRRIAANELLQTIRAATYFMMR ITVVSPGGELQTE(SEQ ID NO.:8);
in a preferred embodiment of the present application, the light chain of the antibody comprises the light chain variable region described above and a light chain constant region, which may be murine.
In the present application, the terms "antibody of the application", "protein of the application", or "polypeptide of the application" are used interchangeably and refer to an antibody that specifically binds to an enoyl-acyl carrier protein reductase (ENR), such as a protein or polypeptide having a heavy chain variable region (e.g., the amino acid sequence of SEQ ID No. 4) and/or a light chain variable region (e.g., the amino acid sequence of SEQ ID No. 8). They may or may not contain an initiating methionine.
The application also provides other proteins or fusion expression products having the antibodies of the application. In particular, the application includes any protein or protein conjugate and fusion expression product (i.e., conjugate and fusion expression product) having heavy and light chains comprising a variable region, provided that the variable region is identical or at least about 90% homologous, preferably at least about 95% homologous, to the variable regions of the heavy and light chains of the antibodies of the application.
In general, the antigen binding properties of antibodies can be described by 3 specific regions located in the heavy and light chain variable regions, called variable regions (CDRs), which are separated into 4 Framework Regions (FRs), the amino acid sequences of the 4 FRs being relatively conserved and not directly involved in the binding reaction. These CDRs form a loop structure, the β -sheets formed by the FR therebetween are spatially close to each other, and the CDRs on the heavy chain and the CDRs on the corresponding light chain constitute the antigen binding site of the antibody. It is possible to determine which amino acids constitute the FR or CDR regions by comparing the amino acid sequences of the same type of antibody.
The variable regions of the heavy and/or light chains of the antibodies of the application are of particular interest because they are involved, at least in part, in binding to an antigen. Thus, the application includes those molecules having monoclonal antibody light and heavy chain variable regions with CDRs, so long as the CDRs are 90% or more (preferably 95% or more, most preferably 98% or more) homologous to the CDRs identified herein.
The application includes not only intact monoclonal antibodies but also fragments of antibodies having immunological activity or fusion proteins of antibodies with other sequences. Thus, the application also includes fragments, derivatives and analogues of said antibodies.
As used herein, the terms "fragment," "derivative," and "analog" refer to polypeptides that retain substantially the same biological function or activity of an antibody of the application. The polypeptide fragment, derivative or analogue of the application may be (i) a polypeptide having one or more conserved or non-conserved amino acid residues, preferably conserved amino acid residues, substituted, which may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent in one or more amino acid residues, or (iii) a polypeptide formed by fusion of a mature polypeptide with another compound, such as a compound that extends the half-life of the polypeptide, for example polyethylene glycol, or (iv) a polypeptide formed by fusion of an additional amino acid sequence to the polypeptide sequence, such as a leader or secretory sequence or a sequence used to purify the polypeptide or a proprotein sequence, or a fusion protein with a 6His tag. Such fragments, derivatives and analogs are within the purview of one skilled in the art and would be well known in light of the teachings herein.
The antibody of the present application refers to a polypeptide having an enoyl-acyl carrier protein reductase (ENR) binding activity, comprising the CDR regions described above. The term also includes variants of polypeptides comprising the above-described CDR regions that have the same function as the antibodies of the application. These variants include (but are not limited to): deletion, insertion and/or substitution of one or more (usually 1 to 50, preferably 1 to 30, more preferably 1 to 20, most preferably 1 to 10) amino acids, and addition of one or several (usually 20 or less, preferably 10 or less, more preferably 5 or less) amino acids at the C-terminal and/or N-terminal end. For example, in the art, substitution with amino acids of similar or similar properties does not generally alter the function of the protein. As another example, the addition of one or more amino acids at the C-terminus and/or N-terminus typically does not alter the function of the protein. The term also includes active fragments and active derivatives of the antibodies of the application.
The variant forms of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA which hybridizes under high or low stringency conditions with the encoding DNA of an antibody of the application, and polypeptides or proteins obtained using antisera raised against an antibody of the application.
The application also provides other polypeptides, such as fusion proteins comprising a human antibody or fragment thereof. In addition to nearly full length polypeptides, the application also includes fragments of the antibodies of the application. Typically, the fragment has at least about 50 contiguous amino acids, preferably at least about 50 contiguous amino acids, more preferably at least about 80 contiguous amino acids, and most preferably at least about 100 contiguous amino acids of the antibody of the application.
In the present application, a "conservative variant of an antibody of the present application" refers to a polypeptide in which at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids are replaced by amino acids of similar or similar nature, as compared to the amino acid sequence of the antibody of the present application. These conservatively variant polypeptides are preferably generated by amino acid substitutions according to Table A.
Table A
Initial residues | Representative substitution | Preferred substitution |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
The application also provides polynucleotide molecules encoding the antibodies or fragments thereof or fusion proteins thereof. The polynucleotides of the application may be in the form of DNA or RNA. DNA forms include cDNA, genomic DNA, or synthetic DNA. The DNA may be single-stranded or double-stranded. The DNA may be a coding strand or a non-coding strand.
Polynucleotides encoding the mature polypeptides of the application include: a coding sequence encoding only the mature polypeptide; a coding sequence for a mature polypeptide and various additional coding sequences; the coding sequence (and optionally additional coding sequences) of the mature polypeptide, and non-coding sequences.
The term "polynucleotide encoding a polypeptide" may include polynucleotides encoding the polypeptide, or may include additional coding and/or non-coding sequences.
The application also relates to polynucleotides which hybridize to the sequences described above and which have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences. The present application relates in particular to polynucleotides which hybridize under stringent conditions to the polynucleotides of the application. In the present application, "stringent conditions" means: (1) Hybridization and elution at lower ionic strength and higher temperature, e.g., 0.2 XSSC, 0.1% SDS,60 ℃; or (2) adding denaturing agents such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll,42℃and the like during hybridization; or (3) hybridization only occurs when the identity between the two sequences is at least 90% or more, more preferably 95% or more. Also, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO.4 and/or SEQ ID NO. 8.
The full-length nucleotide sequence of the antibody of the present application or a fragment thereof can be generally obtained by a PCR amplification method, a recombinant method or an artificial synthesis method. One possible approach is to synthesize the sequences of interest by synthetic means, in particular with short fragment lengths. In general, fragments of very long sequences are obtained by first synthesizing a plurality of small fragments and then ligating them. In addition, the heavy chain coding sequence and the expression tag (e.g., 6 His) may be fused together to form a fusion protein.
Once the relevant sequences are obtained, recombinant methods can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it into a cell, and isolating the relevant sequence from the propagated host cell by conventional methods. The biomolecules (nucleic acids, proteins, etc.) to which the present application relates include biomolecules that exist in an isolated form.
At present, it is already possible to obtain the DNA sequences encoding the proteins of the application (or fragments or derivatives thereof) entirely by chemical synthesis. The DNA sequence can then be introduced into a variety of existing DNA molecules (or vectors, for example) and cells known in the art. In addition, mutations can be introduced into the protein sequences of the application by chemical synthesis.
The application also relates to vectors comprising the above-described suitable DNA sequences and suitable promoter or control sequences. These vectors may be used to transform an appropriate host cell to enable expression of the protein.
The host cell may be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples are: coli, streptomyces; bacterial cells of salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf 9; animal cells of CHO, COS7, 293 cells, and the like.
Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryote such as E.coli, competent cells, which can take up DNA, can be obtained after the exponential growth phase and then treated with CaCl 2 The process is carried out using procedures well known in the art. Another kind ofThe method is to use MgCl 2 . Transformation can also be performed by electroporation, if desired. When the host is eukaryotic, the following DNA transfection methods may be used: calcium phosphate co-precipitation, conventional mechanical methods such as microinjection, electroporation, liposome encapsulation, and the like.
The transformant obtained can be cultured by a conventional method to express the polypeptide encoded by the gene of the present application. The medium used in the culture may be selected from various conventional media depending on the host cell used. The culture is carried out under conditions suitable for the growth of the host cell. After the host cells have grown to the appropriate cell density, the selected promoters are induced by suitable means (e.g., temperature switching or chemical induction) and the cells are cultured for an additional period of time.
The recombinant polypeptide in the above method may be expressed in a cell, or on a cell membrane, or secreted outside the cell. If desired, the recombinant proteins can be isolated and purified by various separation methods using their physical, chemical and other properties. Such methods are well known to those skilled in the art. Examples of such methods include, but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting-out method), centrifugation, osmotic sterilization, super-treatment, super-centrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high Performance Liquid Chromatography (HPLC), and other various liquid chromatography techniques and combinations of these methods.
The antibodies of the application may be used alone or may be conjugated or coupled to a detectable label (for detection purposes).
Detectable labels for detection purposes include, but are not limited to: biotin, fluorescein, chemiluminescent groups, fluorescent proteins, enzymes, colloidal gold, colored magnetic beads, latex particles, biotin labels, radionuclides, antibodies, ligands, antigens, receptors, nanoparticles, or combinations thereof.
Typically, the nanoparticle is selected from the group consisting of: gold nanoparticles, silver nanoparticles, quantum dots, or combinations thereof.
Typically, the enzyme is selected from the group consisting of: horseradish peroxidase, acid phosphatase, or a combination thereof.
Hybridoma cell strain
The application also provides hybridoma cell lines that produce the present application directed to enoyl-acyl carrier protein reductase (ENR) monoclonal antibodies; preferably, the present application provides hybridoma cell lines of high titers against enoyl-acyl carrier protein reductase (ENR) monoclonal antibodies.
After obtaining the hybridoma producing the enoyl-acyl carrier protein reductase (ENR) monoclonal antibody of the application, the hybridoma cell line can be conveniently used by one skilled in the art to prepare antibodies. Furthermore, the structure of the antibodies of the application (e.g., the heavy and light chain variable regions of the antibodies) can be readily known to those skilled in the art, and then the monoclonal antibodies of the application can be prepared by recombinant methods.
Preparation of monoclonal antibodies
Antibodies of the application may be prepared by various techniques known to those skilled in the art. For example, the antigens of the application may be administered to animals to induce monoclonal antibody production. For monoclonal antibodies, hybridoma technology can be used to prepare (see Kohler et al, nature 256;495,1975; kohler et al, eur. J. Immunol.6:511,1976; kohler et al, eur. J. Immunol.6:292,1976; hammerling et al, in Monoclonal Antibodies and T Cell Hybridomas, elsevier, N.Y., 1981) or can be prepared using recombinant DNA methods (U.S. Pat. No.4,816,567).
Representative myeloma cells are those that fuse efficiently, support stable high levels of antibody production by the antibody-producing cell of choice, and are sensitive to the medium (HAT medium matrix), including myeloma cell lines, e.g., murine myeloma cell lines, including those derived from MOPC-21 and MPC-11 mouse tumors (available from Salk Institute Cel l Distribution Center, san diego, california, usa) and SP-2, NZ0 or X63-Ag8-653 cells (available from American Type Culture Collection, rocyveromyces, maryland, usa). Human myeloma and mouse-human hybrid myeloma cell lines have also been described for the production of human monoclonal antibodies [ Kozbor, j.immunol.,133:3001 (1984); techniques and applications for the production of monoclonal antibodies by Brodeur et al (Monoclonal Antibodies Production Techniques and Applications), pages 51-63 (Marcel Dekker, inc., new York, 1987) ].
The culture medium in which the hybridoma cells are grown is analyzed to detect the production of monoclonal antibodies having the desired specificity, such as by an in vitro binding assay, e.g., an enzyme-linked immunosorbent assay (ELISA) or a Radioimmunoassay (RIA). The location of cells expressing the antibody can be detected by FACS. The hybridoma clones can then be subcloned by limiting dilution steps (subcloned) and grown by standard methods (Goding, monoclonal antibody (Monoclonal Antibodies): principles and practices (Principles and Practice), academic Press (1986) pages 59-103). Suitable media for this purpose include, for example, DMEM or RPMI-1640 medium. In addition, hybridoma cells can grow as ascites tumors in animals.
Monoclonal antibodies secreted by the subclones are suitably isolated from culture medium, ascites fluid or serum by conventional immunoglobulin purification procedures such as protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis or affinity chromatography.
The present application provides a monoclonal antibody directed against enoyl-acyl carrier protein reductase (ENR). In a preferred embodiment of the application, the monoclonal antibodies are prepared by culturing hybridoma cells. Taking supernatant of hybridoma cell culture, roughly extracting IgG by a saturated ammonium sulfate precipitation method, and purifying the roughly extracted antibody by an affinity chromatography column (Protein G-Sepharose).
In a preferred embodiment of the present application, the monoclonal antibody is prepared by the method of producing a monoclonal antibody by using Balb/C mouse ascites. Approximately hybridoma cells were inoculated into the abdominal cavity of sensitized mice, and obvious abdominal distension was seen around 10 days. Extracting ascites, coarse extracting with saturated ammonium sulfate precipitation, and purifying the coarse extracted antibody with affinity chromatographic column (Protein G-Sepharose).
The application has the main advantages that:
(1) The antibodies of the application are the first antibodies known to be applicable to enoyl-acyl carrier protein reductase (ENR);
(2) The antibodies of the application are the first antibodies known to be useful in antibiotic screening;
(2) The antibody has the characteristics of high affinity, high specificity, multiple application scenes and the like.
The present application will be described in further detail with reference to the following examples. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application. The following examples are not to be construed as limiting the details of the experimental procedure, and are generally carried out under conventional conditions such as those described in the guidelines for molecular cloning laboratory, sambrook.J.et al, (Huang Peitang et al, beijing: scientific Press, 2002), or as recommended by the manufacturer. Percentages and parts are by weight unless otherwise indicated. The experimental materials and reagents used in the following examples were obtained from commercial sources unless otherwise specified.
Materials and methods
1 antibody production:
the present inventors used the patent technology SEAL of the ibamate company as a production route of the antibody TM . The specific process route is as follows (figure 1):
(1) antigen preparation: synthesis of enoyl-acyl carrier protein reductase polypeptide 'MLRRGFLSRI (SEQ ID NO: 9)' 'PINPADINTI (SEQ ID NO: 10)' 'GANSAVGQAV (SEQ ID NO: 11)' 'AKFKDAAAAA (SEQ ID NO: 12)' as an immunogen, the polypeptide coupled to an immunogenicity enhancing factor that couples VLPs and conventional KLH systems.
(2) Immunized mice
Each group of antigens will be used to immunize 6 Balb/c mice (8-12 weeks old) and their serum titers monitored to determine the optimal number of immunizations. Each immunogenic polypeptide is mixed into a set. Optimized adjuvants and immunization methods are capable of producing high affinity antibodies (IgG subtypes) against most antigenic polypeptides. The mice serum is taken to detect titer after 3 to 4 times of enhancement after primary immunization (the recombinant protein is used as antigen coating, the recombinant protein adopts prokaryotic expression of escherichia coli, and the specific preparation method is shown in Advanced genetic strategies for) recombinant protein expression in Escherichia coli.HP, mortensen kk.j biotechnol.2005jan26;115 (2):113-28.). Mice with acceptable titers will be impacted once and used for fusion, and failed mice will continue to be boosted one to two times to fusion after the titer is highest.
(3) Serum detection and screening: the immunized mice were bled from the orbit and serum titers were detected by ELISA (recombinant proteins as antigen coating). Serum titers were greater than 10K, otherwise boost was continued.
(4) Fusion and screening: whole spleen and 1/2 lymph nodes were taken and fused with myeloma SP2/0 cell line. The process is optimized PEG fusion. The fused cells were plated onto 4 384-well plates (102 to 104 per well) and cultured. The supernatants from all wells were collected, screened for polypeptide detecting precursors by ELISA, and cultured in a positive Kong Zhuaidao 96-well plate with cells visualized. After several days of growth, the supernatants from all wells were collected and assayed for reaction with soluble fragment detector by ELISA. The positive wells further detect soluble fragment detection pro-binding at different dilutions for affinity sequencing. The 20 parent clones with highest affinity for each polypeptide immunogen enter subclones. The 60 parental clones with highest affinity for each soluble fragment immunogen enter subclones.
(5) Subcloning and screening: subcloning is performed by limiting dilution and ELISA screening to obtain monoclonal hybridoma cells. Cells were plated in 96-well plates and cultured to cover about 1/6 of the bottom. ELISA detects the reaction of the supernatant of each hole on the soluble fragment detecting antigen and the corresponding polypeptide detecting antigen, and two holes with high OD value and good cell state are taken to enter the subcloning of the next round. The above procedure was repeated until the cell line positive rate in the wells was 100%. At this point we obtained a monoclonal cell line. After the last round of subcloning, all positive cells were immediately expanded, one part was frozen for later use and the other part was prepared as supernatant or ascites.
(6) Antibody supernatant preparation: finally we obtained 8 monoclonal cell lines and injected F1 mice via the abdomen for antibody production. The ascites produced was purified with Protein A/G and used for subsequent detection.
2 antibody validation
ELISA, western blotting, co-immunoprecipitation, mass spectrometry, antibody chip and the like are carried out on the obtained 8-injection monoclonal antibody cell strain, and the most effective antibody is determined.
Example 1 Elisa (immune enzyme linked) pairing verification of antibodies and antigen polypeptides
And (3) coating the ascites antibody to be paired on a 96-well ELISA plate, incubating, washing, blocking with skimmed milk overnight, washing with PBS, and preserving at 4 ℃ for later use. Antigen polypeptide incubation, PBS wash, and control were set. HRP-labeled detection antibody was added to the ELISA plate incubated with the above. TMB color reaction, and reading by an enzyme label instrument. The titers of 8 cell lines we screened were as follows in table 1:
table 1 8 titers of cell lines
Example 2 endogenous protein imprinting (WB) validation of antibodies
WB validation was performed using whole protein lysate of drosophila, antibody dilution concentrations 1:1000, 1:2000 and 1:5000. The experimental results (FIG. 2) show that anti-ENR (clone 5H 11) can specifically recognize 36kd bands in WB validation, consistent with the expected size.
EXAMPLE 3 Immunoprecipitation (IP) of antibodies plus mass spectrometry validation
1mg of Drosophila total protein was extracted, immunoprecipitation (IP) was performed using anti-ENR (clone 5H 11), and the IP product was excised as a 36kd band for mass spectrometry. The mass spectrum results (as in table 2) show that ENR is enriched in IP samples in large amounts, demonstrating that the antibodies of the application have high specificity for ENR recognition. Furthermore, the antibodies of the application can be applied to IP experiments.
TABLE 2 detection results of 36kd size band mass spectrum for IP products
Example 4 antibody chip detection experiments
anti-ENR (clone 5H 11) antibodies and control antibodies were spotted on NC film-based glass plates using a chip spotter to form antibody spots with a diameter of 100 um. The whole protein of Drosophila was biotin-labeled and incubated at a concentration of 2ug/ml on an antibody chip for half an hour at room temperature. The PBS was gently washed three times, incubated with CY3-SA fluorescent secondary antibody, washed three times with PBS, and the chip was scanned using a GenePix fluorescent chip scanner at 523 nm.
The experimental results show that (figure 3) the anti-ENR antibody has obvious enrichment binding effect on target protein, the fluorescence intensity is strong, and the antigen-antibody binding reaction of the control antibody does not occur.
EXAMPLE 5 detection of the Enacyl-acyl carrier protein reductase content in microorganisms
The antibody can be used as a detection antibody for specifically detecting the content of the enoyl-acyl carrier protein reductase in bacteria, plants, protozoans and mitochondria due to the unique specificity of the antibody to the enoyl-acyl carrier protein reductase, or further developed as a kit. The application has made some preliminary exploratory verification experiments, such as detection experiments in different microorganisms.
Standard substance: recombinant protein of enoyl-acyl carrier protein reductase was quantified by BCA protein and concentration was confirmed by running on a counterstain and diluted at a ratio of 10ug/ml,5ug/ml,2.5ug/ml,1.25 ug/ml.
ELISA experiments of the standard substances are carried out on the detection antibody at a fixed concentration (1 mg/ml), and data (see table 3) are obtained to draw a standard curve (figure 4) for concentration calculation reference for the detection of the subsequent sample to be detected.
Table 3 ELISA rapid assay:
standard substance concentration mg/ml | 10 | 5 | 2.5 | 1.25 |
Standard OD value | 3.001 | 2.287 | 1.621 | 0.994 |
ELISA experiments were performed by obtaining samples of tissue fluid from different crop roots, using the same fixed antibody concentration (1 mg/ml), and the OD values obtained were substituted into the standard curve to calculate the actual protein content in the microorganism, and the results are shown in Table 4 below.
TABLE 4 ELISA test results of tissue fluid samples of different crop roots
Detection of OD value | Protein concentration conversion mg/ml | Expression level | |
Streptococcus sp | 0.855 | 1.107 | High height |
Staphylococcus aureus | 1.034 | 1.332 | High height |
Coli bacterium | 0.595 | 0.845 | In (a) |
Aspergillus niger | 0.087 | 0.499 | Low and low |
All documents mentioned in this disclosure are incorporated by reference in this disclosure as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the application as defined in the appended claims.
Sequence listing
<110> Aibi Mart medicine technologies (Shanghai Co., ltd.)
<120> monoclonal antibodies to enoyl-acyl carrier protein reductase and uses thereof
<130> P2018-0302
<160> 12
<170> PatentIn version 3.5
<210> 1
<211> 11
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 1
Leu Glu Gly Ala Asn Asn Ile Arg Arg Gln Thr
1 5 10
<210> 2
<211> 9
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 2
Ile Arg Arg Met Tyr Phe Gly Gly Pro
1 5
<210> 3
<211> 6
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 3
Gly Ile Phe Val Ala Thr
1 5
<210> 4
<211> 82
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 4
Ser Val Pro Arg Met Tyr Leu Gln Thr Ala Ala Asn Leu Glu Gly Ala
1 5 10 15
Asn Asn Ile Arg Arg Gln Thr Pro Ala Ala Pro Leu Leu Gln Thr Ser
20 25 30
Val Ile Arg Gln Thr Ile Arg Arg Met Tyr Phe Gly Gly Pro Thr Thr
35 40 45
Leu Gln Glu Glu Gly Gly Pro Ala Val Ala Asn Phe Phe Thr Leu Gly
50 55 60
Ile Phe Val Ala Thr Asn Ala Val Ser Pro Pro Gln Gln Leu Thr Glu
65 70 75 80
Gly Arg
<210> 5
<211> 6
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 5
Ile Arg Val Ala Thr Thr
1 5
<210> 6
<211> 7
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 6
Pro Ser Ser Arg Arg Gln Thr
1 5
<210> 7
<211> 7
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 7
Tyr Phe Met Met Arg Ile Thr
1 5
<210> 8
<211> 81
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 8
Val Ala Arg Thr Asn Ile Met Met Phe Ser Pro Ala Val Ala Thr Ile
1 5 10 15
Arg Val Ala Thr Thr Pro Pro Gly Val Ala Gln Gln Leu Glu Pro Ser
20 25 30
Ser Val Pro Gln Thr Thr Glu Pro Ser Ser Arg Arg Gln Thr Met Arg
35 40 45
Arg Ile Ala Ala Asn Glu Leu Leu Gln Thr Ile Arg Ala Ala Thr Tyr
50 55 60
Phe Met Met Arg Ile Thr Val Val Ser Pro Gly Gly Glu Leu Gln Thr
65 70 75 80
Glu
<210> 9
<211> 10
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 9
Met Leu Arg Arg Gly Phe Leu Ser Arg Ile
1 5 10
<210> 10
<211> 10
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 10
Pro Ile Asn Pro Ala Asp Ile Asn Thr Ile
1 5 10
<210> 11
<211> 10
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 11
Gly Ala Asn Ser Ala Val Gly Gln Ala Val
1 5 10
<210> 12
<211> 10
<212> PRT
<213> Artificial sequence (Artificial sequence)
<400> 12
Ala Lys Phe Lys Asp Ala Ala Ala Ala Ala
1 5 10
Claims (14)
1. An antibody against an enoyl-acyl carrier protein reductase polypeptide, wherein the antibody has:
(1) A heavy chain variable region; and (2) a light chain variable region;
the heavy chain variable region contains the following complementarity determining region CDRs:
VH CDR1 shown in SEQ ID NO. 1,
VH CDR2 shown in SEQ ID NO. 2, and
VH CDR3 shown in SEQ ID No. 3;
the light chain variable region contains the following complementarity determining region CDRs:
VL CDR1 shown in SEQ ID No. 5,
VL CDR2 shown in SEQ ID NO. 6, and
the VL CDR3 shown in SEQ ID No. 7, the enoyl-acyl carrier protein reductase polypeptide is 'PINPADINTI'.
2. The antibody of claim 1, wherein the heavy chain variable region has the amino acid sequence set forth in SEQ ID No. 4.
3. The antibody of claim 1, wherein the light chain variable region has the amino acid sequence shown in SEQ ID No. 8.
4. The antibody of claim 1, wherein the antibody has: a heavy chain having the heavy chain variable region and a heavy chain constant region, and a light chain having the light chain variable region and a light chain constant region.
5. A recombinant protein, characterized in that the recombinant protein consists of the following components:
(i) The sequence of the antibody of claim 1; and
(ii) Optionally a tag sequence to assist expression and/or purification.
6. A polynucleotide encoding a polypeptide selected from the group consisting of:
(1) The antibody of claim 1; or (b)
(2) The recombinant protein according to claim 5.
7. A vector comprising the polynucleotide of claim 6.
8. A genetically engineered host cell comprising the vector or genome of claim 7 integrated with the polynucleotide of claim 6.
9. A conjugate, the conjugate comprising:
(a) The antibody of claim 1 or the recombinant protein of claim 5; and
(b) A detectable label attached to the antibody or recombinant protein of (a).
10. An inspection article, the inspection article comprising:
(1) The antibody of claim 1, the recombinant protein of claim 5, or the conjugate of claim 9; and
(2) Optionally a buffer.
11. The test article of claim 10, wherein the test article is used to detect an enoyl-acyl carrier protein reductase.
12. Use of the antibody of claim 1, the recombinant protein of claim 5, or the conjugate of claim 9, or the detection article of claim 10 for the preparation of a detection article or kit for detecting enoyl-acyl carrier protein reductase in a microorganism.
13. A test kit comprising the antibody of claim 1, the recombinant protein of claim 5, or the conjugate of claim 9 or the test article of claim 10.
14. A method for detecting enoyl-acyl carrier protein reductase in a microorganism, the method comprising the steps of:
(a) Providing a sample to be detected;
(b) Mixing the sample with the antibody of claim 1, the recombinant protein of claim 5, the conjugate of claim 9, or the detection article of claim 10 to form a mixture;
(c) Detecting the presence or absence of an "antibody-enoyl-acyl carrier protein reductase complex" in the mixture, wherein the presence of the complex, if any, indicates the presence of enoyl-acyl carrier protein reductase in the sample; if the complex is not present, it indicates that no enoyl-acyl carrier protein reductase is present in the sample.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810464311.1A CN110483642B (en) | 2018-05-15 | 2018-05-15 | Monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810464311.1A CN110483642B (en) | 2018-05-15 | 2018-05-15 | Monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110483642A CN110483642A (en) | 2019-11-22 |
CN110483642B true CN110483642B (en) | 2023-09-26 |
Family
ID=68545445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810464311.1A Active CN110483642B (en) | 2018-05-15 | 2018-05-15 | Monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110483642B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105936896A (en) * | 2016-06-28 | 2016-09-14 | 湖北工业大学 | Preparation and applications of polyclonal antibody of bactericidal enoyl reductase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007093848A2 (en) * | 2005-08-03 | 2007-08-23 | Affinium Pharmaceuticals, Inc. | Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori |
-
2018
- 2018-05-15 CN CN201810464311.1A patent/CN110483642B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105936896A (en) * | 2016-06-28 | 2016-09-14 | 湖北工业大学 | Preparation and applications of polyclonal antibody of bactericidal enoyl reductase |
Non-Patent Citations (1)
Title |
---|
Jiangwei Yao等.Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.Infection and Immunity.2016,第84卷(第12期),第3597-3607页. * |
Also Published As
Publication number | Publication date |
---|---|
CN110483642A (en) | 2019-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6783886B2 (en) | Anti-CTLA4 monoclonal antibody or antigen-binding fragment thereof, pharmaceutical composition and use | |
TWI796328B (en) | B7-h3 antibody, antigen-binding fragment thereof and medical application thereof | |
EP3689909A1 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
JP2021535743A (en) | Anti-CD47 antibody and its applications | |
WO2016188449A1 (en) | Single-domain antibody targeting cd47 | |
CN109206514B (en) | TSLP monoclonal antibody and its preparation method and application | |
WO2019091449A1 (en) | Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof | |
JP2022509930A (en) | Anti-CD73 antibody, its antigen-binding fragment and their use | |
CN112500485B (en) | anti-B7-H3 antibody and application thereof | |
CN110903389B (en) | Monoclonal antibody and cell line for resisting GFAP protein, and preparation method and application thereof | |
US9403913B2 (en) | Anti-VASA antibodies, and methods of production and use thereof | |
WO2018153366A1 (en) | Tim-3 antibody, antigen binding fragment thereof, and medicinal uses thereof | |
CN106866820B (en) | Monoclonal antibody for capturing tumor cells and resisting human keratin 18 and application thereof | |
RU2420588C2 (en) | MURINE MONOCLONAL ANTIBODIES BOUND WITH ANTIGEN F1 OF Yersinia pestis, METHOD FOR PRODUCING THEREOF WITH USING YEAST, METHOD AND KIT FOR Yersinia pestis DETECTION | |
CN110483642B (en) | Monoclonal antibody of enoyl-acyl carrier protein reductase and application thereof | |
CN111349169B (en) | Monoclonal antibody of Werner syndrome ATP dependent helicase and application thereof | |
CN110483641B (en) | Monoclonal antibody of interferon inducible GTPase and application thereof | |
CN109879966A (en) | Humanization design and expression verifying based on source of mouse CD19 antibody | |
CN111349157B (en) | Monoclonal antibody of cadherin 6 and application thereof | |
CN111349171B (en) | Monoclonal antibody of peroxidase-6 and application thereof | |
CN111349170B (en) | Monoclonal antibody of immune related GTPase family M (IRGM) and application thereof | |
CN107987167B (en) | Monoclonal antibody of RNA polymerase II transcription subunit 37e mediator and application thereof | |
CN111349164B (en) | Monoclonal antibody of glycosyl phosphatidyl inositol anchored glycoprotein (C4.4A) and application thereof | |
CN105646712B (en) | Monoclonal antibody and its application | |
CN113929783B (en) | anti-CD 99 protein monoclonal antibody, cell line, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |